significant, measurable clonal proportion of mature blood lineages. [1] [2] [3] [4] [5] Evolution of mutant clonal hematopoiesis with age predisposes the elderly to myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and other aging-associated Letters to the Editor diseases, suggesting that mutations identified in hematopoietic stem cells (HSCs) contribute to disease development. [1] [2] [3] [4] [5] However, the mechanisms by which age-induced stem cell mutations cause clonal expansion of HSCs are largely unknown.
Recently, acquired somatic mutations in TP53 gene were identified in the blood of aged healthy individuals and the frequency of TP53 mutations increases with age.
3-5 TP53 mutations rank top five among mutations identified in aged healthy individuals. [3] [4] [5] The TP53 gene, which encodes the tumorsuppressor p53, is the most frequent target for mutation in human cancer, including hematological malignancies. 6 TP53 mutations are present in 10% of MDS cases and 20-30% in secondary MDS arising after exposure to radiation or alkylating agents. 1, 7 The frequency of TP53 mutations in AML is approximately 10%. However, in AML with complex karyotype, the frequency of TP53 mutations and/or deletions is almost 70%. 8 Further, TP53 mutations are associated with poor prognosis and decreased survival in MDS and AML. [7] [8] [9] However, the role of TP53 mutations in clonal hematopoiesis and the pathogenesis of hematological malignancies is largely unknown.
To date, no studies have investigated the in vivo effect of TP53 mutations expressed from the endogenous locus in hematopoietic cells, which might allow delineation of how these mutations contribute to the pathogenesis of hematological malignancies. [10] [11] [12] [13] The vast majority of missense TP53 mutations are mapped to the DNA-binding domain of p53 protein and usually abrogate its sequence-specific DNA-binding activity. 6 Previous studies show that codon 248 of the p53 protein is most frequently mutated in MDS and AML. 7, 8 p53 R248W mutant has also been identified in aged healthy individuals. [3] [4] [5] To better understand the role of mutant p53 in hematopoiesis when expressed physiologically from its endogenous promoter, we utilized the humanized p53 R248W knock-in mice, expressing human p53 mutant protein from the endogenous murine Trp53 promoter.
14 Given that most TP53 mutations in clonal hematopoiesis and hematological malignancies are monoallelic missense mutations, [3] [4] [5] [6] [7] [8] [9] we examined HSC function in the heterozygous p53 R248W/+ mice to recapitulate clinical conditions. We first analyzed the peripheral blood (PB) and bone marrow (BM) of p53 +/+ and p53 R248W/+ mice (8-12 week old). PB cell counts and BM cellularity were comparable among these mice (Supplementary Figures S1a-f) . In p53 knockout mice, there is a dramatic increase of long-term HSCs 11 ; however, we found that p53 +/+ and p53 R248W/+ mice have a similar number of long-term HSCs (Figure 1a and Supplementary Figure S1g ). In addition, the expression of p53 R248W did not affect the frequency of myeloid progenitors (Figures 1a and b , and Supplementary Figure S1g) . To determine the role of p53 R248W in hematopoiesis in vivo, we performed competitive BM transplantation assays as shown in Supplementary Figure S1h Figure S1i ). p53 R248W did not affect myeloid and lymphoid differentiation in the PB and the BM of the primary recipient mice (Figures 1f and g ). We then transplanted 3 × 10 6 BM cells isolated from the primary recipient mice into lethally irradiated secondary recipients. Sixteen weeks after transplantation, p53 R248W/+ cells continued to show increased repopulating ability (Figure 1h ). p53 R248W did not affect myeloid and lymphoid differentiation in the PB of secondary recipients (Figure 1i ). These findings suggest that the expression of mutant p53 in normal HSCs does not cause leukemic transformation but rather generates a premalignant state. 15 HSCs in aged mice have decreased per cell repopulating activity, self-renewal and homing abilities, myeloid skewing of differentiation and increased apoptosis with stress. 1, 16 To determine the role of mutant p53 in hematopoiesis during aging, we maintained the secondary transplantation recipient mice shown in Figure 1h for 412 months. We observed enhanced repopulating potential of p53 R248W/+ BM cells compared with p53 +/+ cells 48 weeks after transplantation ( Figure 1j ). We found decreased frequency of donor-derived myeloid cells and increased frequency of lymphoid cells in the PB of the recipients repopulated with p53 R248W/+ cells (Figure 1k ). Tumor suppressor p53 regulates HSC quiescence and response to genotoxic stress. 11 Given that p53 -/-mice are resistant to 5-fluorouracil (5-FU) treatment, 10 we hypothesized that p53 R248W/+ mice may be resistant to chemotherapy treatment. We treated p53 +/+ and p53 R248W/+ mice with 5-FU weekly and then monitored their survival. Although most wild-type mice died 4 weeks following 5-FU treatment, all p53 R248W/+ mice were still alive (Figure 2a) . To measure the kinetics of hematopoietic recovery, we administered a single dose of 5-FU (200 mg/kg) and serially followed PB cell counts. 5-FU-treated p53 R248W/+ mice had less severe leukopenia than p53 +/+ mice, with more rapid recovery (Figure 2b, Supplementary Figures S2a-d) . We treated p53 +/+ and p53 R248W/+ mice with one dose of 5-FU (200 mg/kg) and then examined BM cellularity, HSC frequency and apoptosis 1 week later. We found that p53 R248W/+ mice exhibited higher BM cellularity compared with To determine whether functional TP53 mutations promote clonal expansion of HSCs following chemotherapy treatment, we generated mixed BM chimaeras containing both p53 +/+ and p53 R248W/+ cells (the ratio of p53 +/+ to p53 R248W/+ cells is 10:1). Eight weeks following transplantation, recipient mice were treated with DMSO or chemotherapy drug N-ethyl-N-nitrosourea (ENU), respectively (Supplementary Figure S3a) . Although DMSO treatment did not affect the repopulating ability of p53 R248W/+ HSCs, p53
R248W/+
HSCs outcompeted p53 +/+ cells and become clonal dominance upon ENU treatment (Figure 2k ). ENU treatment did not affect the differentiation of p53 +/+ and p53 R248W/+ HSCs in the PB of recipient mice (Supplementary Figure S3b) . The frequency of mutant LSKs was significantly increased in the BM of recipient mice at 16 weeks following ENU treatment (Figure 2i and Supplementary Figure S3c) . We sacrificed the recipient mice at 16 weeks following DMSO or ENU treatment and then performed pathological analysis to detect tumor formation. Although there were no tumors in recipient mice treated with DMSO, four out of the seven recipient mice treated with ENU developed lymphoma or thymoma (data not shown).
Given p53-null HSCs are less sensitive to irradiation, [11] [12] [13] we examined the impact of mutant p53 on HSC function following irradiation. We found that HSCs expressing mutant p53 show decreased apoptosis and increased repopulating potential compared with wild-type HSCs following irradiation. Furthermore, p53 R248W/+ HSCs show competitive advantage over p53 +/+ cells and underwent clonal expansion following total body irradiation (SC and YL, unpublished data).
Thus we have identified a critical role for mutant p53 in regulating the response of HSCs to genotoxic stresses. Further, we discovered that chemotherapy and radiotherapy cause the expansion of HSCs expressing mutant p53. Although mutant p53 proteins accumulate in cancer cells, the levels of mutant p53 proteins in normal cells are very low. 14, 17 Genotoxic stresses stabilize mutant p53 in hematopoietic cells. 14, [17] [18] Given that the p53 R248W mutant has both dominant-negative and gain-offunction roles in human cancer, 6, 14 stabilized mutant p53 may inhibit the wild-type p53 function or gain new oncogenic functions through protein-protein interactions to promote leukemic transformation. In addition, the expansion of mutant HSCs following genotoxic stresses may increase the possibility of acquiring additional genetic and/or epigenetic changes that facilitate leukemic transformation. Showalter Trust Fund New Investigator Award, an Alex Lemonade Stand Foundation grant, a Children's Leukemia Research Association grant and an American Cancer Society Institutional Research Grant to YL. We thank the Flow Cytometry Core and In vivo Therapeutic Core Laboratories, which were sponsored, in part, by the NIDDK Cooperative Center of Excellence in Hematology (CCEH) grant U54 DK106846. This work was supported, in part, by a Project Development Team within the ICTSI NIH/ NCRR Grant Number UL1TR001108. We also thank Dr. Yang Xu at USCD for providing the p53 R248W mice to the study.
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